Physician profile
Jaime Mitchell
NPI 1477963924
$3,560.51
in general payments reported to CMS, 2019-2025
24 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $139 · 2024: $1,492 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.73 |
| Education | $292.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,013.83 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $392.91 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $341.56 | 2021-2025 | |
| Organogenesis INC. | $219.88 | 2022-2025 | Cygnus Dual, Via Matrix, Puraply Wound Matrix |
| Regeneron Healthcare Solutions, INC. | $205.24 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $176.36 | 2024-2025 | |
| Ucb, INC. | $171.81 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $162.95 | 2024-2025 | |
| Pfizer INC. | $144.63 | 2024-2025 | |
| Incyte Corporation | $139.68 | 2024-2025 | Opzelura |
| Boston Scientific Corporation | $106.27 | 2022 | |
| Amgen INC. | $82.95 | 2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $63.64 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $63.22 | 2024-2025 | |
| Leo Pharma INC. | $47.09 | 2025 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $40.32 | 2024 | Vtama |
| Organon LLC | $35.32 | 2025 | Hadlima, Vtama |
| Galderma Laboratories, L.P. | $34.24 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.85 | 2024 | Spevigo |
| Davol INC. | $23.33 | 2021 | |
| Genentech USA, INC. | $20.85 | 2024 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $16.56 | 2024 | Sotyktu |
| Smith+Nephew, INC. | $15.60 | 2025 | Grafix Pl, Oasis, Pico |
| Verrica Pharmaceuticals INC. | $15.42 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.